Study of FP-1039 in Subjects With Endometrial Cancers
Status:
Withdrawn
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
An open-label, non-randomized, single arm study to assess the safety, tolerability, and
pharmacokinetics of FP-1039 given by weekly intravenous (IV) administrations in advanced
endometrial cancer patients with FGFR2-specific mutations. FP-1039 will be dosed weekly
starting at a dose of up to 16 mg/kg.